Compare AstraZeneca plc (AZN) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Stryker Corporation — how do they compare? AstraZeneca plc trades at $158.4 (market cap $248.14B), while Stryker Corporation trades at $346.82 (market cap $133.54B). The key difference: AstraZeneca plc is the larger of the two by market cap, and AstraZeneca plc pays the higher dividend (2.01%). Which is the better fit depends on your goals.
| AZN | SYK | |
|---|---|---|
Market Cap | $248.14B | $133.54B |
Sector | Health | Technology |
52-Week High | $209.48 | $394.34 |
52-Week Low | $147.06 | $282.58 |
Enterprise Value | $275.41B | $145.01B |
Dividend Yield | 2.01% | 1.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
Stryker (SYK) trades at $347.21, up 0.4% today, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals, including a 9% organic sales growth in Q2 2026 and a net income margin of 14.43%. Recent news highlights recovery from a cybersecurity incident and the launch of Mako RPS, expanding its robotic surgery portfolio. Analyst consensus is overwhelmingly positive, with 74% recommending Buy and a price target of $379.44.
The outlook for SYK is favorable, driven by robust earnings growth and strategic product launches. Key risks include cybersecurity vulnerabilities and margin pressures from tariffs. With no sell ratings and strong institutional support, the stock presents a compelling opportunity for growth-oriented investors, though monitoring quarterly execution remains critical.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
